Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
ONTARIO SHARED SERVICES has floated a tender for Project: Tender_18543 - Molecular Assay for Drug Resistant Tb Testing. The project location is Canada and the tender is closing on 21 May 2024. The tender notice number is 163524001, while the TOT Ref Number is 100694695. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : Canada
Summary : Project: Tender_18543 - Molecular Assay for Drug Resistant Tb Testing
Deadline : 21 May 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 100694695
Document Ref. No. : 163524001
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
PHO believes that the following procurement qualifies as a sole source or single source procurement. The purpose of this Advanced Contract Award Notice (ACAN) is to determine if there are other proponents capable of meeting the requirements of the procurement for the following supplies for PHO. Vendor: Becton Dickinson Canada Inc Product: BD Max MDR-TB Assay Purpose: A Health Canada approved assay for the detection of drug resistant Mycobacterium tuberculosis. The drug resistance targets sought as part of this assay are for isoniazid and rifampin. PHO has a requirement a commercial Health Canada approved molecular assay for detection of drug resistant Mycobacterium tuberculosis, with drug resistance targets of isoniazid and rifampin. Recent changes to the Canadian Tuberculosis Standards require a test with a short turnaround time to determine prompt treatment for individuals with M. tuberculosis detected by molecular assays. As such, PHO requires supply of an assay which is capable of detecting multidrug resistant tuberculosis from clinical specimens, as well as culture isolates. PHO believes that the BD MAx MDR-TB Assay is the only commercial Health Canada approved assay for this use capable of detecting isoniazid and rifampin resistant M. tuberculosis. PHO intends to award a 5 year term contract (comprised of 2 firm years and 3 one-year options) to Becton Dickinson for the products described above.
Solicitation Type : ACAN - Advance Contract Award Notice (Formal)
Reference Number : 00004041652
Location : Ontario
Purchase Type : Not Stated
Dates Publication : 2024/05/01 11:14:00 AM EDT
Closing Date : 2024/05/21 11:00:00 AM EDT
Contact Information : Jonathon Martynski
: jonathon.martynski@oahpp.ca
:
Description : PHO believes that the following procurement qualifies as a sole source or single source procurement. The purpose of this Advanced Contract Award Notice (ACAN) is to determine if there are other proponents capable of meeting the requirements of the procurement for the following supplies for PHO. Vendor: Becton Dickinson Canada Inc Product: BD Max MDR-TB Assay Purpose: A Health Canada approved assay for the detection of drug resistant Mycobacterium tuberculosis. The drug resistance targets sought as part of this assay are for isoniazid and rifampin. PHO has a requirement a commercial Health Canada approved molecular assay for detection of drug resistant Mycobacterium tuberculosis, with drug resistance targets of isoniazid and rifampin. Recent changes to the Canadian Tuberculosis Standards require a test with a short turnaround time to determine prompt treatment for individuals with M. tuberculosis detected by molecular assays. As such, PHO requires supply of an assay which is capable of detecting multidrug resistant tuberculosis from clinical specimens, as well as culture isolates. PHO believes that the BD MAx MDR-TB Assa...
Documents
Want To Bid in This Tender?
Get Local Agent Support in Canada and 60 More Countries.
View Tenders By
Sign in with Google